Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

NCT07505615 is registered in ClinicalTrials.gov with Ding-Wei Ye as lead sponsor.

NCT NCT07505615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07505615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Lead sponsor
Ding-Wei Ye
Phase
Phase 1/2
Overall status
Completed
Start date
October 12, 2021
Completion date
May 30, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc